Whitehawk Therapeutics, Inc. Overview
Pro stress-test →Whitehawk Therapeutics is a preclinical stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Its advanced three-asset antibody drug conjugate (ADC) portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.
Strategic Profile
Pro stress-test →The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in March 2025. With a preclinical-stage focus and partnerships in biomarker-driven oncology research, the company is positioning itself in the competitive ADC therapeutics space where multiple players are advancing novel approaches to cancer treatment.
Competitive Landscape
Pro stress-test →Whitehawk operates in the crowded ADC oncology space competing with established biotech companies and other preclinical programs. Key competitive dynamics include differentiation through ADC engineering improvements, biomarker selection, and partnership strategies for clinical development and commercialization.
Industry Context
Whitehawk Therapeutics, Inc. operates in Biotechnology / Oncology Therapeutics.
Key facts
Founded: 2007 · Headquarters: Morristown, New Jersey · Employees: 22 · Revenue: $0 · Market cap: $123-134M